Brazil Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Brazil Pharmaceuticals & Healthcare Report

The Brazil Pharmaceuticals and Healthcare Report

Independent 5-year pharmaceutical and healthcare industry forecasts for Brazil.

Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Brazilian pharmaceutical and healthcare industry.

Competitive intelligence, Brazilian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Brazilian market.

The Brazil Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.

Business Monitor International’s Brazil Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Brazilian pharmaceutical and healthcare industry.

Key Benefits of Report

Coverage

Executive Summary & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.

Market Summary

Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.

Regulatory Regime

Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.

BMI 5-Year Industry Forecast

5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.

BMI 5-Year Macroeconomic Forecasts

BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt

Competitive Landscape & Profiles

Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.

Brazil Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Table of Contents

Chapter - Executive Summary

Brazil Pharmaceuticals And Healthcare Industry SWOT
Brazil Political SWOT
Brazil Economic SWOT
Brazil Business Environment SWOT

Chapter - Pharmaceutical Business Environment Ratings

Table: Americas Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns

Chapter - Brazil – Market Summary

Regulatory Regime
Intellectual Property
Regulator Interference
Data Protection
Compulsory Licensing
Intellectual Property Environment
Pricing And Reimbursement Issues
Tax Burden On Pharmaceuticals
Over-The-Counter Regulations
Advertising
Other Regulatory Issues

Chapter - Industry Developments

Epidemiology
Healthcare Sector
Domestic Pharmaceutical Industry
PROFARMA Initiative
Research and Development

Chapter - Industry Forecast Scenario

Overall Market Forecast
Table: Brazilian Drug Market Trends
Key Growth Factors – Industry
Table: Brazilian Health Expenditure Trends

Chapter - Key Growth Factors – Macroeconomic

Table: Brazil - Economic Activity
Prescription Market Forecast
Table: Brazil's Prescription Drug Market Trends (US$mn unless otherwise stated)
Generics Market Forecast
Table: Brazil's Generics And Patented Market Forecasts
OTC Market Forecast
Table: Brazil's OTC Market Trends (US$mn unless otherwise stated)
Medical Device Market Forecast
Table: Brazil Medical Device Forecasts (US$mn unless otherwise stated)
Table: Pharmaceutical Trade Data And Forecasts (US$mn)
Other Healthcare Data Forecasts
Table: Socio-Demographic Forecasts
Key Risks To BMI's Forecast Scenario

Chapter - Competitive Landscape

Leading Products
Innovative Drugmakers
Generic Drugmakers
OTC Sector
Distribution Sector
Retail Market

Chapter - Company Monitor

Leading Multinational Companies
Sanofi-Aventis
Pfizer
Merck & Co
Novartis
GlaxoSmithKline (GSK)
Roche
Nycomed (Altana Pharma)
Merck KGaA
Novo Nordisk
Indigenous Manufacturing Sector
Aché / Biosintética
EMS Sigma
Eurofarma
Medley

Chapter - Country Snapshot: Brazil Demographic Data

Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2003
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 1999-2004
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 1996-2002

Chapter - BMI Forecast Modelling

How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
Brazil Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Executive Summary

Brazil is one of the most attractive countries in Latin America for multinational pharmaceutical companies. Pharmaceutical market growth stepped up a gear in 2008, registering an increase of 9.5% year-on-year (y-o-y). Sales, including hospitals and other public and private institutions, reached BRL30.8bn (US$16.7bn), showing resilience to the economic downturn and reinforcing Brazil's position as a rapidly expanding and attractive market – one that remains the tenth largest globally. Over the next five years, BMI forecasts that sales of pharmaceuticals will increase from US$16.7bn to US$28.2bn, representing a compound annual growth rate (CAGR) of 11.0%.

In BMI’s Pharmaceuticals & Healthcare Business Environment Rankings for Q209, Brazil places fourth in the Americas region. Despite large market size and high growth rates and low generic penetration, a small pensionable population and weak intellectual property scores will limit progression up the table over the medium term.

Brazil’s use of compulsory licensing to not only to save cost, but also boost production, remains a major risk to multinationals. In early 2009 state-owned pharmaceutical company Farmanguinhos began producing efavirenz, following the National Health Surveillance Agency (ANVISA)’s approval. The Ministry of Health received its first order of 2.1mn tablets on February 16 2009, with a total order for 15mn over the course of the year. By 2010, the target for production is 30mn, which will cover total demand of the population, essentially eliminating the need for imports of the drug. Efavirenz is used by 85,000 of the 185,000 people in Brazil's AIDS programme. BMI questions whether producing a generic version of a patented drug, which could be procured cheaper elsewhere, essentially undermines the fundamentals of the original compulsory licence – to save money.

Despite their relatively low penetration, generics continue to capture market share in Brazil. Sales of generic drugs rose 33% in 2008, while, in volume terms, the number of units sold rose 18.9% to 277.1mn. Despite an evident reluctance to use, we believe that prevailing economic conditions should help further develop the market over the course of 2009.

Despite certain market constraints, innovative companies are still performing strongly. AstraZeneca's sales in Brazil grew at double that of the retail pharmaceutical market in 2008, placing the drugmaker in ninth position, with a market share of 3.3%. Meanwhile, Switzerland-based Roche also showed strong performance in Brazil in 2008, with sales growing 9% to BRL1.7bn (US$0.95bn).

Brazil Pharmaceuticals & Healthcare Report
Was: $1030.00
Now: $875.00
You save: $155.00 (15%)
Read about our other Pharmaceuticals & Healthcare Reports

Africa

Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe

Asia

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam

Caribbean

Puerto Rico

Europe

Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan

Latin America

Argentina, Chile, Colombia, Mexico, Peru and Venezuela

Middle East

Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates

North America

Canada and United States
Business Monitor International Business Monitor International
A Market Leader in Country Risk, Industry Intelligence and Company Research

Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK

BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world.

Country Risk Analysis and Forecasts
BMI
has for 25 years specialised in political risk analysis, financial markets analysis, and macroeconomic forecasts on 175 global markets.

Industry Intelligence and Market Research
BMI's industry research covers Automotives; Banking; Chemicals; Defence & Security; Food & Drink; Freight Transport; Information Technology; Infrastructure; Insurance; Mining; Oil & Gas; Petrochemicals; Pharmaceuticals & Healthcare; Power; Telecommunications, and Tourism.

Company Research
BMI maintains a fully-researched 55,000-site database of multinational company subsidiaries located across global markets.